perugu_vada Posted September 13, 2020 Report Posted September 13, 2020 Pfizer CEO Albert Bourla said the drugmaker should have key data from its late-stage trial for the Food and Drug Administration by the end of October. If the FDA approves the vaccine, the company is prepared to distribute "hundreds of thousands of doses," he said. On Saturday, Pfizer submitted a proposal to the FDA to expand the late-stage trial to include up to 44,000 participants, a significant increase from its previous target of 30,000. Quote
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.